Researchers identify DPY30 as an epigenetic target to sensitize pancreatic tumors to immunotherapy. UC San Diego researchers redirect CMV immunity against pancreatic cancer in preclinical models. A Fred Hutch researcher receives ACS grant to study immunotherapy resistance in melanoma.
Scientists at Cincinnati Children's have identified a molecular pathway responsible for immune checkpoint inhibitor-induced myocarditis and demonstrated that blocking TNF signaling can prevent this fatal complication without compromising anti-tumor efficacy.
Researchers have developed a remote-controlled CAR T-cell therapy that can be switched off on demand using venetoclax, while new engineering strategies aim to overcome barriers in treating glioblastoma and other solid tumors.
Precision oncology has transformed brain metastases treatment from lung cancer, extending survival from 6-12 months to 3-5 years through targeted therapies, immunotherapy, and radiosurgery. With 100,000-200,000 annual cases in the US, multidisciplinary approaches now manage this once-terminal condition as a chronic disease.
Researchers develop a nanoplatform that co-induces cuproptosis and disulfidptosis to upregulate PD-L1 expression and sensitize tumors to immune checkpoint blockade therapy, addressing resistance in PD-L1-low malignancies.
Research shows TET2-driven clonal hematopoiesis improves immune checkpoint blockade efficacy in solid tumors, while separate studies identify new immune pathways in childhood brain cancers and mechanisms behind immunotherapy resistance.
Researchers in China and Australia have identified distinct mechanisms to improve cancer immunotherapy effectiveness, addressing why up to 60% of patients fail to respond to immune checkpoint blockade therapy.
